Skip to main content
. Author manuscript; available in PMC: 2022 Aug 15.
Published in final edited form as: Bioorg Med Chem. 2021 Jul 11;44:116307. doi: 10.1016/j.bmc.2021.116307

Figure 3. Cellular activity of compound 17 is consistent with GGDPS inhibition while monophosphonates 27 and 11 show no activity.

Figure 3.

RPMI-8226 cells were incubated for 48 hours in the presence or absence of lovastatin (10 μM, Lov) or varying concentrations of compounds 17, 27 or 11. A and C) Immunoblot analysis of H-Ras, unmodified Rap1a (uRap1a; antibody detects only unmodified protein) and β-tubulin (as a loading control) was performed. The gels are representative of three independent studies. B and D) Intracellular lambda light chain concentrations were determined via ELISA. Data are expressed as percentage of control (mean ± SD, n=3). The * denotes p<0.05 per t-test and compares treated cells to untreated control cells.